Hot or cold: Bioengineering immune contextures into in vitro patient-derived tumor models

Adv Drug Deliv Rev. 2021 Aug:175:113791. doi: 10.1016/j.addr.2021.05.001. Epub 2021 May 7.

Abstract

In the past decade, immune checkpoint inhibitors (ICI) have proven to be tremendously effective for a subset of cancer patients. However, it is difficult to predict the response of individual patients and efforts are now directed at understanding the mechanisms of ICI resistance. Current models of patient tumors poorly recapitulate the immune contexture, which describe immune parameters that are associated with patient survival. In this Review, we discuss parameters that influence the induction of different immune contextures found within tumors and how engineering strategies may be leveraged to recapitulate these contextures to develop the next generation of immune-competent patient-derived in vitro models.

Keywords: Immune checkpoint inhibitors; Immune contexture; Organoids; Tumor microenvironment; Tumor models.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immunotherapy / methods*
  • Neoplasms / drug therapy
  • Neoplasms / immunology
  • Tissue Engineering / methods*
  • Tumor Cells, Cultured / immunology*

Substances

  • Immune Checkpoint Inhibitors